Transgene Stock

Transgene Net Debt

The Net Debt of Transgene (TNG.PA) as of Aug 25, 2026 is -6.44 M EUR. In the previous year, Net Debt was 1.54 M EUR — a change of -518.60% (lower).

Net Debt

-6.44 MEUR

YoY

-518.60%

Last updated:

Net Debt of Transgene is 2026 -6.44 M EUR. Net Debt of Transgene was 2025 1.54 M EUR. It decreases by -518.60% lower compared to the previous year.

The Transgene Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
769,000.00 EUR
Jan 1, 2018
8.15 M EUR
Jan 1, 2019
-27.45 M EUR
Jan 1, 2020
-21.23 M EUR
Jan 1, 2021
-45.73 M EUR
Jan 1, 2022
-13.31 M EUR
Jan 1, 2023
1.54 M EUR
Jan 1, 2024
-6.44 M EUR
The Transgene Net Debt history
YEARNet DebtYoY
-6.44 MEUR-518.60%
1.54 MEUR-111.56%
-13.31 MEUR-70.89%
-45.73 MEUR+115.38%
-21.23 MEUR-22.66%
-27.45 MEUR-436.67%
8.15 MEUR+960.21%
769,000.00EUR-107.01%
-10.97 MEUR-330.45%
4.76 MEUR-116.01%
-29.73 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Net Debt of Transgene is -6.44 M EUR in 2026.

Net Debt of Transgene changed from 1.54 M EUR to -6.44 M EUR, representing a -518.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Transgene since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Transgene historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Transgene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transgene